1. Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease
John D. Sheppard, MD, MMSc, Gail L. Torkildsen, MD, John D. Lonsdale, MD, Francis A. D'Ambrosio, MD, Eugene B. McLaurin, MD, Richard A. Eiferman, MD, Kathryn S. Kennedy, PhD, MSE, Charles P. Semba, MD 
Ophthalmology 
Volume 121, Issue 2, Pages (February 2014)
DOI: /j.ophtha
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

2. Figure 1
Corneal fluorescein staining score in a study of lifitegrast compared with placebo for dry eye disease. Results for the inferior, superior, central, and total corneal regions (Ora scale) using mean change from baseline to day 84 analysis (*2-sided t test). LIF = lifitegrast; ODS = ocular discomfort score; SE = standard error.
Ophthalmology  , DOI: ( /j.ophtha )
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

3. Figure 2
Conjunctival lissamine staining score in a study of lifitegrast compared with placebo for dry eye disease. Results for nasal and total conjunctival regions (Ora scale) using mean change from baseline analysis (*2-sided t test, §Wilcoxon rank-sum test). LIF = lifitegrast; SE = standard error.
Ophthalmology  , DOI: ( /j.ophtha )
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

4. Figure 3
Key symptom scores in a study of lifitegrast compared with placebo for dry eye disease. The ocular discomfort zone (Ora scale; left) and Eye Dryness score (visual analog scale, right) at all visits (*2-sided t test). LIF = lifitegrast; SE = standard error.
Ophthalmology  , DOI: ( /j.ophtha )
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions